Jennifer Linge

Stories

GLP-1 weight loss drugs face scrutiny over muscle loss, but new research suggests fears may be overblown

As of May 2026: Active researcher

More than 30 million Americans now take GLP-1 receptor agonist drugs like Ozempic and Wegovy to lose weight. A persistent concern has dogged the medications since their rise: that they burn through muscle along with fat, leaving patients weaker even as they get thinner.

Updated May 30